CRMD Myron Kaplan buys $276K worth of shares
Oct 28, 2025, 4:35 AM
0.00%
What does CRMD do
CorMedix is a pharmaceutical company based in New Jersey, focused on developing therapeutic products, notably DefenCath, an antimicrobial solution for preventing catheter-related bloodstream infections in kidney failure patients. The company went public in 2010 and has also sponsored research on taurolidine for rare pediatric tumors.
Myron Kaplan bought 25,000 shares of CRMD on 23 October at $11.02 per share, worth a total of $276K. They now own 201,034 CRMD shares, or a 14% holding increase.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.